Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Tedopi vs Chemotherapy in Advanced NSCLC
NCT02654587Phase 3Terminated
- Sponsor
- OSE Immunotherapeutics
- Start
- Feb 2016
- Primary completion
- Jan 2021
- Modality
- Prophylactic Vaccines, Peptides, Therapeutic Vaccines
- Countries
- 10
01
Overview
Phase 3, randomised, open-label trial of Tedopi in non-small cell lung cancer (NSCLC) (2 arms), sponsored by OSE Immunotherapeutics. Primary endpoint: Overall Survival at 24 months. Started Feb 2016; status: terminated.
02
Drugs
Tedopi
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT02654587.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02654587.